Abstract
A substantial amount of experimental evidence implicates neuropeptide Y (NPY) in the pathophysiology of epilepsy. Over the past 20 years, remarkable progress has been made in unraveling the mechanisms and receptors involved in the anticonvulsant effect of this abundantly expressed neuropeptide. Activation of Y2 and/or Y5 receptors and blockade of Y1 receptors in the central nervous system suppresses seizures in a variety of animal seizure models. Orally available, brain penetrating Y2 and/or Y5 agonists, and possibly Y1 antagonists, may therefore constitute a novel class of antiepileptic drugs, which could greatly benefit patients with medically refractory epilepsy. Significant progress has been made in identifying non-peptidergic Y1 antagonists that fulfill these criteria, but suitable Y2 and/or Y5 agonists have proven to be more elusive. Innovative oral and parental drug delivery strategies which are currently under development may offer a means of using the more readily available peptidergic NPY receptor ligands in a clinical setting. Finally, gene therapy, antisense probes or RNA interference strategies which alter the expression of NPY or its receptors in specific brain regions may also be of use in the treatment of epilepsy, but will probably benefit a smaller subgroup of epilepsy patients, since they typically require an invasive procedure.
Keywords: Neuropeptide Y, NPY, ligands, epilepsy
Current Topics in Medicinal Chemistry
Title: Clinical Potential of Neuropeptide Y Receptor Ligands in the Treatment of Epilepsy
Volume: 7 Issue: 17
Author(s): Alfred Meurs, Ralph Clinckers, Guy Ebinger, Yvette Michotte and Ilse Smolders
Affiliation:
Keywords: Neuropeptide Y, NPY, ligands, epilepsy
Abstract: A substantial amount of experimental evidence implicates neuropeptide Y (NPY) in the pathophysiology of epilepsy. Over the past 20 years, remarkable progress has been made in unraveling the mechanisms and receptors involved in the anticonvulsant effect of this abundantly expressed neuropeptide. Activation of Y2 and/or Y5 receptors and blockade of Y1 receptors in the central nervous system suppresses seizures in a variety of animal seizure models. Orally available, brain penetrating Y2 and/or Y5 agonists, and possibly Y1 antagonists, may therefore constitute a novel class of antiepileptic drugs, which could greatly benefit patients with medically refractory epilepsy. Significant progress has been made in identifying non-peptidergic Y1 antagonists that fulfill these criteria, but suitable Y2 and/or Y5 agonists have proven to be more elusive. Innovative oral and parental drug delivery strategies which are currently under development may offer a means of using the more readily available peptidergic NPY receptor ligands in a clinical setting. Finally, gene therapy, antisense probes or RNA interference strategies which alter the expression of NPY or its receptors in specific brain regions may also be of use in the treatment of epilepsy, but will probably benefit a smaller subgroup of epilepsy patients, since they typically require an invasive procedure.
Export Options
About this article
Cite this article as:
Meurs Alfred, Clinckers Ralph, Ebinger Guy, Michotte Yvette and Smolders Ilse, Clinical Potential of Neuropeptide Y Receptor Ligands in the Treatment of Epilepsy, Current Topics in Medicinal Chemistry 2007; 7 (17) . https://dx.doi.org/10.2174/156802607782340975
DOI https://dx.doi.org/10.2174/156802607782340975 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genome-Wide Expression Analysis of Valproate Action: A Systems Level Synthesis
Current Psychopharmacology Addressing Alzheimer’s Disease and Cognitive Loss through Autophagy
Current Neurovascular Research Glutamate Dehydrogenase as a Promising Target for Hyperinsulinism Hyperammonemia Syndrome Therapy
Current Medicinal Chemistry Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets Pharmacological Histone Deacetylation Distinguishes Transcriptional Regulators
Current Topics in Medicinal Chemistry Drug Therapy for Patients with Eating Disorders
Current Drug Targets - CNS & Neurological Disorders Preface
Current Drug Targets - CNS & Neurological Disorders Efficacy and Tolerability of Lacosamide for Focal Epileptic Patients: Study from Epilepsy Clinic in Makkah
CNS & Neurological Disorders - Drug Targets The Yin and Yang of BK Channels in Epilepsy
CNS & Neurological Disorders - Drug Targets Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
Mini-Reviews in Organic Chemistry ERRATUM 2
Current Neuropharmacology Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Whole Embryo Culture: An Important Tool in Developmental Toxicology Today
Current Pharmaceutical Design The Doublecortin Gene Family and Disorders of Neuronal Structure
Central Nervous System Agents in Medicinal Chemistry Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Using Endogenous Neural Stem Cells to Enhance Recovery from Ischemic Brain Injury
Current Neurovascular Research Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology The Biology of the RNA Binding Protein Guanine-Rich Sequence Binding Factor 1
Current Protein & Peptide Science Synthesis and Antioxidant Activity of Indole Derivatives Containing 4-Substituted Piperazine Moieties
Letters in Drug Design & Discovery Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals